Liv Thommesen
Overview
Explore the profile of Liv Thommesen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
796
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heck K, Lindholm H, Niederdorfer B, Tsirvouli E, Kuiper M, Flobak A, et al.
Proteomes
. 2023 Jan;
11(1).
PMID: 36648961
Colorectal cancer (CRC) is one of the most prevalent cancers, driven by several factors including deregulations in intracellular signalling pathways. Small extracellular vesicles (sEVs) are nanosized protein-packaged particles released from...
2.
Folkesson E, Niederdorfer B, Nakstad V, Thommesen L, Klinkenberg G, Laegreid A, et al.
Sci Rep
. 2020 Nov;
10(1):20946.
PMID: 33239689
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
3.
Niederdorfer B, Toure V, Vazquez M, Thommesen L, Kuiper M, Laegreid A, et al.
Front Physiol
. 2020 Aug;
11:862.
PMID: 32848834
Discrete dynamical modeling shows promise in prioritizing drug combinations for screening efforts by reducing the experimental workload inherent to the vast numbers of possible drug combinations. We have investigated approaches...
4.
Folkesson E, Niederdorfer B, Nakstad V, Thommesen L, Klinkenberg G, Laegreid A, et al.
Sci Rep
. 2020 Jul;
10(1):11574.
PMID: 32665693
Drug combinations have been proposed to combat drug resistance, but putative treatments are challenged by low bench-to-bed translational efficiency. To explore the effect of cell culture format and readout methods...
5.
A high-throughput drug combination screen of targeted small molecule inhibitors in cancer cell lines
Flobak A, Niederdorfer B, Nakstad V, Thommesen L, Klinkenberg G, Laegreid A
Sci Data
. 2019 Oct;
6(1):237.
PMID: 31664030
While there is a high interest in drug combinations in cancer therapy, openly accessible datasets for drug combination responses are sparse. Here we present a dataset comprising 171 pairwise combinations...
6.
Mjelle R, Sjursen W, Thommesen L, Saetrom P, Hofsli E
BMC Cancer
. 2019 Feb;
19(1):161.
PMID: 30786859
Background: MicroRNAs (miRNA) and other small RNAs are frequently dysregulated in cancer and are promising biomarkers for colon cancer. Here we profile human, virus and bacteria small RNAs in normal...
7.
Cobo I, Martinelli P, Flandez M, Bakiri L, Zhang M, Carrillo-de-Santa-Pau E, et al.
Nature
. 2018 Feb;
554(7693):533-537.
PMID: 29443959
Chronic inflammation increases the risk of developing one of several types of cancer. Inflammatory responses are currently thought to be controlled by mechanisms that rely on transcriptional networks that are...
8.
Mjelle R, Sellaeg K, Saetrom P, Thommesen L, Sjursen W, Hofsli E
Oncotarget
. 2017 Nov;
8(52):90077-90089.
PMID: 29163812
MicroRNAs (miRNAs) are promising prognostic and diagnostic biomarkers due to their high stability in blood. Here we investigate the expression of miRNAs and other noncoding (nc) RNAs in serum of...
9.
Rao S, Solum G, Niederdorfer B, Norsett K, Bjorkoy G, Thommesen L
BMC Cancer
. 2017 Jan;
17(1):68.
PMID: 28109268
Background: The peptide hormone gastrin exerts a growth-promoting effect in both normal and malignant gastrointestinal tissue. Gastrin mediates its effect via the cholecystokinin 2 receptor (CCKBR/CCK2R). Although a substantial part...
10.
Tripathi S, Vercruysse S, Chawla K, Christie K, Blake J, Huntley R, et al.
Database (Oxford)
. 2016 Jun;
2016.
PMID: 27270715
A large gap remains between the amount of knowledge in scientific literature and the fraction that gets curated into standardized databases, despite many curation initiatives. Yet the availability of comprehensive...